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Sarcoma is the common denominator for malignant tumors of mesenchymal origin. 
Sarcomas encompass almost 100 diagnoses with different histology, molecular 
features and natural history, and may present in any part of the body. The most 
common sarcoma in the abdomen is the gastrointestinal stromal tumor (GIST). GIST 
is most frequent in the stomach followed by the small intestine, yet can occur 
throughout the gastrointestinal tract. The first line of treatment for GIST is complete 
surgical resection, if feasible. Since the discovery of targeted small-molecule 
therapy with imatinib in 1998 and the successful treatment of the first GIST patient 
two years later, this therapy has attracted much attention and GIST has become a 
model system for modern oncological treatment. This thesis is based on translational 
research in the field of sarcoma with the main focus on GIST. In paper I, a proof-of-
concept study of intracellular imatinib measurements is presented. Cell-cultures of 
imatinib-sensitive and resistant cells were exposed to imatinib in different 
concentrations. The analysis was performed with liquid chromatography mass 
spectrometry and time-of-flight detection (LC/MS-TOF). The imatinib-resistant cell-
line had significantly lower imatinib concentrations. Clinical samples from three 
patients were analyzed using the same protocol and showed imatinib accumulation 
in tissue and a large variability between patients. In paper II, the importance of 
surgical technique and surgical margins was studied. Resecting GIST with a wide 
margin of >2 cm normal tissue and intact covering peritoneum, lead to improved 
recurrence-free survival. The impact of the margin was independent when adjusting 
for other known risk factors such as size, site and mitotic index. Paper III analyzed 
an expanded cohort of imatinib treated and resected GIST using an improved, 
updated protocol for mass spectrometry and drug transporter expression analysis. 
The previous finding of large intra- and interpatient variability of imatinib 
concentrations was confirmed. Plasma and tissue concentrations were not correlated 
to the response. Low expression of drug transport proteins was correlated to the 
improved histological response. Finally, paper IV is a nested case-control study and 
describes trends in breast sarcoma incidence in Sweden during the period of 1993-
2003, showing a 4-fold increase of angiosarcoma. The angiosarcoma patients were 
overrepresented as carrying a history of breast cancer with the highest risk 5-10 
years after their breast cancer diagnosis (OR 167, CI 95% 35.1-791; p<0.001). This 
points to the possibility that the increased use of radiotherapy could be a reason for a 
rise in incidence of angiosarcoma. 
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Sarcoma is the general description of malignant tumors arising from mesenchymal 
cells and can develop in any part of the body. The mesenchymal origin separates 
sarcomas from carcinomas, which originate from epithelial cells. Sarcoma is a 
heterogeneous group of diseases with low incidence in the population. It contains 
several different diagnoses, traditionally categorized by their tissue of origin, such as 
lipocytes being the precursor of liposarcoma, smooth- or skeletal muscle cells 
transforming into leiomyosarcoma and rhabdomyosarcoma, respectively.  
 The first known reference of sarcoma dates back to 1500 BC when a text on a 
papyrus roll describes a “fatty tumor” and recommends that it should be treated with 
the knife [1]. The term sarcoma was coined by the Greek physician, Galen, who was 
active in Rome in the late 2nd century where he, among other things, acted as a 
surgeon for gladiators. The term is derived from the Greek word sarkos (σαρκός) 
meaning meat, based on the appearance of soft tissue tumors [1, 2]. The meaning of 
sarcoma as well as other terms describing soft tissue tumors was, however, ill-
defined and varied among physicians through the centuries. In the mid 19th century 
the use of microscopical examination of tissue, including tumors, grew in popularity. 
In 1858-1859 three authors, Virchow, Gross and Wilks, almost simultaneously 
published features that distinguish sarcoma from carcinoma [1]. The first 
classification system for sarcomas was published in 1902 by the German pathologist 
Borst [3]. During the 20th century, following numerous case reports and studies, new 
and expanded classifications of sarcomas were proposed by Ewing in 1919 [4] and 
Stout in 1953 [5]. The World Health Organization (WHO) publishes and regularly 
updates a classification system for soft tissue and bone tumors, i.e. sarcomas. The 
first edition was published in 1969 [6] and was originally based on histology; 
however, with emerging knowledge, the 4th edition, which was released in 2013, 
specifically emphasizes the increased use of molecular genetics in the sarcoma 
diagnosis [7, 8]. The latest version, the 5th edition, released in May 2020, further 
expands classifications of sarcomas and based on genetic rearrangement and 
mutation, introduces new subgroups and diagnoses into the sarcoma group [9]. 
Currently, the group of diseases known as sarcomas, comprises around 100 
histologically and/or molecularly different tumors and with the increased use of 
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molecular pathology and understanding of different entities, new subtypes are 
continuously added while others are reclassified [10]. 
 The nomenclature in sarcoma literature may be confusing and there are still 
several different classifications and grading systems in use. Sarcomas are most often 
categorized by location into extremity sarcoma (ES) or sarcoma of the trunk, 
including visceral sarcoma (VS) and retroperitoneal sarcoma (RPS). Based on the 
site (tissue) of origin, the tumors can also be classified as bone sarcoma (BS) or soft 
tissue sarcoma (STS). Historically, soft tissue sarcomas were often clustered, 
without regard for histology, in order to facilitate inclusion in clinical trials, therein 
producing doubtful results [11, 12].  
 In lack of a commonly accepted nomenclature and registration praxis, available 
reports differ in subdivision of tumor sites and types. This makes pooling of data 
from different studies of this heterogeneous group of tumors and comparisons of 
populations rather challenging [13]. 
1.1 EPIDEMIOLOGY OF SARCOMA 
Since sarcomas are a heterogeneous group of rare tumors and definitions are still 
evolving, conclusive and comparative epidemiological data is scarce. Different 
health care databases have been studied with varying results. 
 Perhaps the most comprehensive epidemiological data comes from the 
European RARECARE project that accumulates data on cancers with incidence of 
less than 6/100 000/year from European cancer registries. Sarcoma cases are 
classified based on tumor site and to some extent, morphology. In a recent overview 
with data from 94 cancer registries within RARECARE, trends in incidence rate and 
survival were analyzed for 73 795 patients with soft tissue sarcoma in the period 
2000-2007. The crude incidence for soft tissue sarcoma was 4.7/100 000 person-
years (male 4.4, female 5.0). The annual incidence for STS of viscera was 0.4 per 
100 000. GIST was reported separately with an incidence of 0.3/100 000/year. The 
incidence for RPS was 0.3/100 000/year. Standardized incidence rates were 
calculated compared to the European population [14]. In an earlier analysis of the 
RARECARE cohort covering 45 568 incident sarcoma cases from 76 population-
based cancer registries between 1995 and 2002, higher incidence in northern Europe 
and lower incidence in eastern Europe were observed. This study also reported 
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survival analysis data for STS based on tumor site. Overall, five-year survival was 
estimated to 57.8%, with the worst prognosis for sarcoma of the heart (10.7%) and 
mediastinum (15.3%). For VS five-year survival was 45.6% and for GIST, which 
was analyzed separately, it was 67.7%. Sarcoma of the pelvis had an estimated five-
year survival of 42.2% and RPS 42.0%. Trend analysis indicated improved survival 
over time, especially for VS and sarcoma of the trunk [15]. 
 Trautman et al. studied health insurance data for the population in Saxony, 
Germany between 2005 and 2012 comprising 2 615 865 individuals and reported an 
annual age standardized incidence of STS to be 4.5/100 000 [16]. A French-Italian 
study of sarcoma incidence over a two-year period in three regions with a total of 26 
million inhabitants, distinguishes between STS in extremities, trunk wall and 
retroperitoneum as well as malignant mesenchymal tumors in internal organs, VS. 
The overall annual incidence in this study was reported to be 5.76/100 000 
consisting of 3.58 STS/100 000 and 2.18 VS/100 000, while the age standardized 
incidence adjusting for the 19 age groups in the 2000 US standard population (ASR-
US) was 5.12/100 000 [17, 18]. 
 Another study that highlights the difficulties in identifying sarcoma cases was 
conducted in France where central histopathological review was used to 
prospectively classify cases of sarcoma. The study was performed in a population-
based manner with a population of 6 million during the period March 2005 to 
February 2007. The overall yearly incidence was 3.6/100 000 for STS and 2.0 for 
VS. The world age standardized incidence was 2.8/100 000 for STS and 1.4 for VS. 
In this study, the most common histological type was GIST, which comprised 18% 
of cases with a yearly incidence of 1.1/100 000 followed by unclassified sarcoma 
(16%; 1/100 000), liposarcoma (15%; 0.9/100 000) and leiomyosarcoma (11%; 
0.7/100 000) [19]. 
 In a population-based study from Denmark during 1979-2008, the age 
standardized incidence for STS was found to be 1.4/100 000 [20]. In addition, a 
study from the Osaka Cancer registry, covering 8.7 million people, identified 6 998 
incident cases of STS during the period 1978-2007. The age-standardized incidence 
rate of STS (ASR-US) was 2.7/100 000 (male 2.8, female 2.6). The trend during the 
second 10-year period showed increased incidence in both genders, however non-
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significant amongst males. The most common subtype was leiomyosarcoma in 
digestive organs and GIST followed by leiomyosarcoma in other locations and 
liposarcoma. As an indication of the diagnostic difficulties while studying sarcoma, 
the authors found that after registration of the first GIST-case in 1988 there was an 
increase of this diagnosis and a simultaneous decrease in diagnosis of 
gastrointestinal leiomyosarcoma [21]. 
 In a study from two regions in Spain between 1981-2005, the annual incidence 
of sarcoma in the gastrointestinal (GI)-tract was found to be 0.42/100 000 persons in 
the early study period (1981-1985) and 1.18 in the late period (2001-2005). In the 
second studied region no data was presented for the early period; however, in the 
later period, authors found 1.36 cases/100 000 persons/year. Cases were analyzed 
with immunohistochemistry for KIT to confirm cases of GIST and the result was an 
incidence of 1.24/100 000/year [22]. Analysis of the SEER registry covering about 
26% of the US population during the period 1973-2006 reported an incidence for 
STS of 5.9/100 000 persons/year. The incidence was lowest in the pediatric 
population younger than 10 years, 0.9/100 000/year and highest for persons older 
than 70 years, 18.2/100 000/year. Notably, this study included Kaposi´s sarcoma 
[23]. In another study from the US, Porter et al. reported data from the SEER 
registry during the period 1973-2001 and analyzed the incidence of retroperitoneal 
sarcoma (RPS). A total of 2 348 cases were identified and the annual incidence was 
calculated to 2.7 per 1 000 000. There was no significant difference in incidence 
over time according to this study [24]. Interestingly, a Finnish study examined 
previous cancer and treatment with chemotherapy, radiation or a combination of 
both and the risk for development of sarcoma. Patients with primary cancer of the 
breast, uterus, lung, ovary, prostate, rectum or lymphoma diagnosed in 1953-2000, 
were included and followed longitudinally. Outcomes were compared to the 
expected number of cases based upon current incidence figures and the standardized 
incidence ratios (SIR) were calculated. After ten years of follow-up, SIR for 
sarcoma was increased in all study groups. Among patients who had received neither 
radiotherapy nor chemotherapy, SIR was 2.0 (95% CI 1.3–3.0), for radiotherapy 
alone SIR was 3.2, (95% CI 2.3–4.3), for chemotherapy alone SIR was 4.9, (95% CI 
1.0–14.4) and for combined radio/chemotherapy SIR was 3.4, (95% CI 0.4–12.5) 
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[25]. The reason for elevated risk among patients receiving neither chemo- nor 
radiotherapy might be underlying susceptivity to developing malignant tumors, such 
as p53 mutations [26, 27], but it is more likely that the incidence figures used to 
calculate SIR underestimate the true incidence in the reference population. Another 
possible explanation could be surveillance bias during follow-up of patients with 
previous malignancies. A weighted case control study might have provided a truer 
estimation of the risk. 
 Finally, a French study of the period 2000-2013 using centralized 
histopathological review, based on the 4th edition of the WHO classification, reports 
a crude annual incidence of 7.4/100 000. In this material, sarcomas constitute 1.3% 
of all diagnosed malignancies. Recalculated into age-standardized incidence rates 
compared to the world population, the overall sarcoma incidence was 5.0/100 
000/year including 2.68 STS, 0.81 gastrointestinal and 0.82 in the female genital 
tract. The authors encourage future investigators to use similar inclusion criteria in 
order to facilitate comparison between studies [13]. 
 In summary, the reported annual incidence for STS ranges from 1.15 to 
5.9/100 000, where the higher incidences include Kaposi´s sarcoma. The incidence 
for VS or intraabdominal sarcoma was reported to be between 1.18 and 2.18/100 
000/year. The incidence of RPS was reported to be 0.27-0.3/100 000/year.  
 There was high heterogeneity between these studies that explained some of the 
differences but there was also, in many studies, a trend of increasing incidence over 
time. This may reflect the fact that sarcomas were being under-diagnosed or under-
reported. Another explanation could be that general health is improving and 
malignant tumors develop more often in an ageing population. Furthermore, 
advances in genomics and molecular testing have brought about changes in 
classification of sarcomas. Some subgroups seem to increase in number, e.g. GIST 
and solitary fibrous tumors, while others, like fibrosarcoma, seem to decrease. The 





Due to the rarity and heterogeneity of these tumors, referral to expert centers is 
recommended if there is suspicion of sarcoma [28, 29]. For the same reasons, no 
clear-cut recommendations on diagnostic work-up can be given for the entire group.  
Usually, suspicion of sarcoma is raised based on radiological findings or a palpable 
mass. Complete radiological examination with different modalities is important in 
order to assess tumor growth in vicinity to vital organs and the presence of 
metastatic disease. The most important investigation for optimizing treatment is to 
obtain a biopsy from the tumor. Different techniques can be used including fine 
needle aspiration, core needle or in selected cases, open biopsy. Care should be 
taken to pass the needle through a channel that can be excised in a later operation or 
in cases of abdominal/retroperitoneal sarcoma, not to pass the peritoneal cavity [28]. 
The risk of tumor seeding in the needle channel is expected to be low, although 
several case reports describe this phenomenon. A meta-analysis pooling data from 
four studies including 547 patients, records 2 cases of presumed needle tract seeding 
(0.37%) [30].  
 Recently, a retrospective study of more than 12 500 patients diagnosed with 
sarcoma between 2010-2014 showed improved recurrence-free survival (RFS), more 
R0 resections and less reoperations for patients presented at multi-disciplinary tumor 
board at an expert sarcoma center prior to surgery as to compared to those patients 
who were not. Notably, 87.7% of patients managed at a sarcoma center had a pre-
operative biopsy, compared to 41.9% of patients treated in other settings [31]. This 
finding is in accordance with previous reports emphasizing the multidisciplinary and 
centralized management of these rare tumors [28, 29, 32, 33]. 
1.3 GRADING AND STAGING 
Different systems have been established in order to predict prognosis. Tumor 
“grade” characterizes the tumor as such, whereas “stage” describes the disease 
burden in terms of severity of the primary tumor, yet also describes the presence of 
metastases. There are several systems for assessment of tumor grade and prognosis. 
One of the most frequently used in sarcoma is the three-tier system proposed by the 
French Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC). This 
system is based upon tumor differentiation, mitotic activity and necrosis [34] (Table 
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1). All factors are assessed and the resulting scores are added: Score 2-3 equals 
Grade 1, score 4-5 Grade 2 and score 6-8 Grade 3. It is the most validated in use, 
however, other grading systems are also used [35]. The National Cancer Institute 
(NCI) Grading system outlines several histological subtypes of sarcoma and assigns 
them to different grades. For example, according to this system, a well-differentiated 
liposarcoma is always grade 1 and a synovial sarcoma is always grade 3, whereas a 
leiomyosarcoma can be grade 1-3. The latter is distinguished by using a combination 
of number of mitoses, pleomorphism, cellularity, matrix and necrosis. The weight 
assigned to each factor also differs for the histologic subtypes; for instance in 
malignant fibrous histiocytoma (MFH), pleomorphism is used to separate grade 2 
from grade 3 although, in leiomyosarcoma, mitotic count is of greater importance 
for separating grades [36]. For subtypes of sarcomas, especially GIST, separate 
grading systems have been developed, see section 2.6. 
 
Score Tumor differentiation 
Mitoses 









2  Certain histological typing 
(biphasic synoviosarcoma, 
alveolar soft-part sarcoma, 
myxoid liposarcoma) 
10-19 >50% 
3 Undifferentiated sarcomas, 
embryonal sarcomas and 





Table 1. FNCLCC grading for sarcoma, adapted from Trojani et al. 1984 [34]. 
 
The American Joint Committee on Cancer (AJCC) has recently updated its TNM 
based staging system for sarcoma [37]. T staging of sarcoma is based on tumor size, 
grade according to FNCLCC and location. The updated version has been validated 
and compared to earlier versions. Although it has a wider span of tumor sizes for T 
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stage, the correlation with overall survival is comparable to the earlier version [38, 
39]. For sarcomas in extremities, trunk and retroperitoneum T stages are: 
 
pT1: Tumor ≤ 5 cm in greatest dimension 
pT2: Tumor >5 cm and ≤10 cm in greatest dimension 
pT3: Tumor >10 cm and ≤15 cm in greatest dimension 
pT4: Tumor >15 cm in greatest dimension 
 
 
There is also a separate TNM staging for abdominal and thoracic visceral organs, 
where the T stage is defined according to involved organs, rather than tumor size: 
 
pT1: Organ confined tumor 
pT2: Tumor extension into tissue beyond organ 
pT2a: Invades serosa or visceral peritoneum 
pT2b: Extension beyond serosa 
pT3: Invades another organ 
pT4: Multifocal involvement 
pT4a: Multifocal (2 sites) 
pT4b: Multifocal (3 - 5 sites) 
pT4c: Multifocal (> 5 sites) 
 
 
Lymph node metastases are generally rare in sarcoma, although some subtypes may 
be more prone to involve lymph nodes [40].  
 To further assess prognosis in sarcoma and aid clinicians in decision-making, 
different nomograms may be used and are often more specific to the underlying 
histology. The nomograms try to predict risk of recurrence and proportion of overall 
survival based on known risk factor such as the patients age, tumor size, grade and 
histology, accounting for the fact that some risk factors are continuous variables. 
Some of these nomograms for risk assessment of retroperitoneal sarcoma (primary 






The most common intraabdominal sarcoma, or sarcoma of the GI-tract, is 
gastrointestinal stromal tumor (hereafter referred to as GIST) [17, 19, 42]. GIST 
originates from Cajal´s interstitial cells or its progenitor and can arise in any part of 
the GI tract. The most common site is the stomach (55-65%) followed by the small 
intestine (25-32%). More unusual locations are esophagus (about 2-3.5%), 
duodenum (about 3%) and colorectal (about 3-6 %) [43-46]. In Sweden, the annual 
incidence of GIST has been reported to be 1.45 per 100 000 inhabitants and the 
prevalence 12.9 / 100 000 [47]. About two-thirds of GIST patients present with 
symptoms, most commonly GI bleeding (overt or microscopical causing anemia) or 
a palpable mass; however, symptoms may also include vague abdominal discomfort, 
dysphagia, early satiety and in rare cases, bowel obstruction and intestinal 
perforation. The remaining cases are mainly discovered as incidental findings on 
radiology, endoscopy or during surgery for other conditions [48]. The clinical course 
in GIST ranges from small indolent tumors to aggressive metastasized sarcomas and 
the treatment protocols must be personalized. More than 70% of patients can be 
cured with surgical resection alone. In cases with a high risk of recurrence, adjuvant 
therapy should be recommended after surgery [49]. The prognosis of advanced 
GIST has changed dramatically after introducing molecularly targeted treatment 
with imatinib and other Tyrosine kinase inhibitors (TKIs). In the pre-imatinib era, 
GIST was a disease with high mortality (Figure 1).  
 
Figure 1. Estimated overall survival in 259 patients with GIST 1983-2000 compared to age and gender 
matched controls. Risk groups according to NIH criteria [47]. Reprinted with permission. 
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2.1 MOLECULAR PATHOLOGY 
GIST was first described as a separate pathologic entity in the 1980s and the tumors 
were previously often classified as schwannomas, leiomyomas or leiomyosarcomas 
[50-52]. GIST morphology can be spindle cell or epithelioid and may be difficult to 
distinguish from other potential diagnoses. Using immunohistochemistry, several 
markers are available for diagnostic purposes. The most often used markers are KIT 
(CD117) and DOG-1, which are mutually over-expressed in almost all GISTs [53]. 
However, 2.6% of GISTs are reported to be negative for both these markers [54]. 
Other markers can be useful in difficult cases and rare GIST with doubtful staining 
of the commonly used antibodies (Table 3). 
 
Protein marker Proportion positive in 
GIST 
KIT (CD117) 95% 
DOG1 ≈98% 
PKC theta 85% 
CD34 60-70% 
Smooth-muscle actin 30-40% 
S100 5% 
Table 3. Immunohistochemical profile of GIST [55-57]. 
 
 KIT is a receptor tyrosine kinase present on the surface of many different cells. 
In normally functioning cells, the receptor is activated by its ligand, stem cell factor. 
Binding of stem cell factor to the receptor causes dimerization and ATP mediated 
activation of downstream signaling pathways, thus promoting cell proliferation [58]. 
The c-kit gene was cloned in 1998 by Hirota, who proposed Cajal´s interstitial cells 
as the cell of origin for GIST [59]. The most common underlying mutations in GIST 
involve the c-kit gene and account for about 75% of cases. Notably, KIT expression, 
detected with the CD117-antibody, is present in a larger proportion of GIST and is 
not diagnostic for mutations in the c-kit gene. About 10% of GISTs have a mutation 
in the PDGFRA (platelet-derived growth factor alpha) gene, encoding a 
transmembrane tyrosine kinase similar to KIT (Figure 2). The remaining 15% of 
GIST (often called wild type) can harbor mutations in genes encoding succinyl 
dehydrogenase (SDHA/B/C/D) (about 6%), BRAF 600E (about 2%), or extremely 
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rare mutations such as HRAS, NRAS, phosphoinositide 3-kinase (PIK3CA), or 




Figure 2. Schematic distribution of KIT and PDGFRA mutations in GIST and potential sensitivity to first-, 
second- and third-line TKI (IM - imatinib, SU - sunitinib and RE - regorafinib). Note that KIT D816V and 
PDGFRA D842V mutations are resistant to all approved lines of TKI. Adapted from Corless et al. 2014 [45], 




 Mutations in c-kit predict the clinical course as well as the response to 
pharmacological therapy. The most common mutation is found in exon 11 and 
causes conformation changes of the protein, which allows for activation in the 
absence of the ligand. These mutations are typically sensitive to treatment with 
imatinib. The second most common mutation is in exon 9. This mutation is almost 
exclusively seen in intestinal GIST and very seldom in gastric GIST. Exon 9 
mutated GIST has a lower sensitivity to imatinib and a double dose of 800 mg daily 
is recommended to treat these tumors [45]. Mutational analysis is also essential in 
order to identify genotypes resistant to TKI, like in PDGFRA on codon 842 
(D842V) [62] (Figure 2). 
D816V 
D842V 
Exon 9 (8%) 
Exon 11 (65%) 
Exon 13 (1%) 
Exon 17 (1%) 
Incl D816V 
Exon 12 (2%) 
Exon 14 (rare) 
Exon 18 (8%) 
Incl D842V 
Exon 14 (rare) 
IM SU RE 
Juxtamembrane domain 
ATP binding pocket 
Kinase insert 
Activation loop 
Ligand binding domain 
Regulation of dimerisation 
KIT (75%) PDGFRA (10%) 
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 DOG1 (Discovered On GIST-1), also known as TMEM16A or ANO1 is a 
Ca2+-activated Cl- channel (CaCC), that is overexpressed in more than 95% of all 
GISTs and is a reliable marker for immunohistochemical diagnosis in combination 
with KIT [54, 63]. This Cl- channel is present in many different cell types 
throughout the body. Its function is not fully understood but in mouse models, 
knockdown experiments have shown that it is essential since its absence caused 
severe tracheomalacia and death within the first month [64]. The ion channel is 
activated when the intracellular concentration of free Ca2+ increases due to release 
from intracellular stores or influx through other plasma membrane channels [65]. 
Studies on GIST cell lines have shown that DOG1 can be activated and inhibited by 
pharmacological and electric stimulation. Activation of DOG1 by Ca2+ or membrane 
depolarization induces Cl- currents, whereas blocking DOG1 might shift early 
apoptotic cells to late apoptosis [66]. Further studies have shown that blocking 
DOG1 may have anti-tumoral effects in vitro by inducing G1 cell cycle arrest and 
reduce colony formation. DOG1 might be a potential future target for GIST 
treatment [67].  
2.2 THE TYROSINE KINASE INHIBITOR IMATINIB 
Imatinib was one of the first targeted therapies against cancer and its discovery was 
the result of a large drug-screening project. The target for imatinib was the Bcr-Abl 
fusion transcript protein that has tyrosine kinase activity and is expressed in the 
majority of chronic myeloid leukemias (CML). The Bcr-Abl fusion gene is formed 
by the translocation between chromosomes 9 and 22, consequently leading to 
formation of the so-called Philadelphia chromosome [68]. Since the structure of the 
Bcr-Abl fusion protein was not known, the development was made by testing a large 
drug library in vitro. After finding a lead compound that was a weak inhibitor of 
protein kinase C (PKC) and PDGFR tyrosine kinases, it was optimized for inhibition 
of PDGFR. The resulting compound, known as experimental drug STI-571 (later 
Glivec®, Gleevec® or imatinib), proved to be a potent inhibitor of auto-
phosphorylation of v-Abl, PDGF receptors and KIT receptors. Clinical trials treating 
Philadelphia chromosome positive CML commenced in June 1998 [69]. That same 
year, the c-kit gene was cloned [59] and the first patient with progressing 
metastasized GIST was treated successfully in 2000 [70].  
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 Imatinib acts on the intracellular domain of the KIT receptor where it has 
affinity to the ATP-binding motif, thereby blocking it and preventing auto-
phosphorylation and activation of downstream signaling. The underlying mutation in 
c-kit or PDGFRA genes and resulting conformation changes in the receptor aids in 
the prediction of sensitivity to imatinib treatment (Figure 2).  
 Imatinib is still the mainstay treatment of inoperable or metastasized GISTs. It 
is also used for neoadjuvant and adjuvant therapy [71].  
2.3 DIAGNOSIS AND TREATMENT 
While many GISTs are asymptomatic and are accidentally discovered while 
performing investigations for other conditions, approximately 2/3 of all GISTs 
present with symptoms such as GI bleeding, bowel obstruction or a palpable mass 
[48]. The tumor is often first detected either by endoscopy or computed tomography 
(CT) scan. Both investigations should be included in the primary evaluation of 
GIST. CT gives information on tumor site, size, over-growth to other organs and 
presence of metastases. In selected cases (notably rectal GIST), MRI is useful for 
detailed anatomical assessment. Endoscopy with biopsy gives the morphological 
diagnosis. Since tumor growth is submucosal, forceps biopsy is often non-diagnostic 
and fine needle biopsy guided by endoscopic ultrasound is the investigation of 
choice. In metastatic disease, percutaneous biopsy can be utilized but is otherwise 
normally discouraged. Therefore, when the tumor is located in the small bowel, pre-
operative biopsy can often not be performed without risk of dissemination. In this 
situation surgery can be planned without an additional diagnostic work-up. This may 
also be the case in other anatomical locations where it is not possible to perform a 
pre-operative diagnostic biopsy yet the tumor is otherwise primarily resectable [48, 
72]. As mentioned above, immunohistochemical diagnosis is typically based on the 
expression of KIT (CD117) and DOG1. Typical histopathological pictures of GIST 






Figure 3. Histologic images of GIST.  Hematoxylin eosin (H&E) stain at x200 magnification (A), H&E stain 
at x400 magnification (B), CD117 (KIT) stain (C), and DOG1 stain (D). 
 
2.4 NEOADJUVANT THERAPY 
In cases with advanced tumors, in which primary resection is not possible without 
severe morbidity due to anatomical site of the tumor or tumor size/overgrowth on 
adjacent organs, neoadjuvant therapy may be considered. The decision to start 
neoadjuvant therapy should be multidisciplinary. Mutational analysis to assess 
potential TKI sensitivity should be performed. In order to evaluate efficacy of 
adjuvant therapy, 18fluoro-deoxy glucose positron emission tomography/computed 
tomography (FDG-PET/CT) is helpful. Typically, an FDG-PET/CT scan is 
performed before starting neoadjuvant therapy and is then repeated after a few 
weeks of therapy. If effective, the glucose uptake in the tumor should decrease 







Figure 4. Small-intestinal GIST in the pelvis during neoadjuvant treatment with imatinib, 400 mg daily. Left 
panel FDG-PET/CT before start of treatment, right panel FDG-PET/CT four weeks after start of treatment, 
showing decreased metabolic activity and decreased size of the tumor. Mutation analysis showed an insertion 
in c-kit exon 11. 
 
 
Further follow-ups with conventional CT or MRI after, e.g. 3 and 6 months, are 
encouraged in order to detect failure of down-staging [73, 74]. Regression of tumor 
size during neoadjuvant therapy with imatinib can usually be expected within the 
first six months, after which maximum response is achieved and the patient should 
be reevaluated for surgery within 6-12 months from start of treatment [71, 75]. 
2.5 SURGERY 
Surgery is the cornerstone in treating GIST. For non-metastatic GIST the treatment 
of choice is complete resection of the tumor without lymph node clearance and 
surgery alone could be curative [71, 76, 77]. Small GISTs can be locally resected, 
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whereas larger tumors may require resection of adjacent organs in order to achieve 
clear margins. The tumors are often soft and may partially only be covered by a 
peritoneal surface; hence, a careful surgical approach is mandatory. Special care 
should be taken not to damage the tumor, since perioperative tumor rupture puts the 
patient at the same risk for recurrence as preoperative rupture or highly malignant 
tumors [78]. Margins can be assessed by the R system [79] or in accordance with 
other soft tissue sarcomas by the system proposed by Enneking [80]. The R system 
is based on the residual tumor after resection and comprises the following 
categories: 
 
RX not assessable 
R0 no microscopic residual tumor at the resection margin 
R1-microscopic residual tumor at the resection margin 
R2 macroscopic residual tumor at the resection margin 
 
The original Enneking definition is cited below: 
“1. Intralesional. An intralesional margin is accomplished by a procedure in which the dissection 
passes within the lesion. Macroscopic or microscopic tumor is left at the margins of the wound, and 
there is contamination of all the exposed tissue planes. Most commonly, local intralesional 
procedures are performed as a diagnostic incisional biopsy, by curettage of a presumably benign 
lesion, or by subtotal removal of a lesion to be managed by other means. An intralesional 
amputation is sometimes intended as a palliative procedure, but more commonly is done 
inadvertently because of occult microextensions of the lesion.  
2. Marginal. A marginal margin is achieved by a procedure in which the lesion is removed in one 
piece. The plane of dissection is through the pseudocapsule or reactive tissue about the lesion, and 
when performed for malignant lesions, leaves microscopic disease at the margin of the wound in a 
high percentage of the cases. As a local procedure, marginal excision is usually described as 
excisional biopsy or “shell ’em out” of a presumed benign lesion. Marginal amputation is usually 
done as either a palliative procedure, an attempted definitive procedure constrained by anatomic 
inaccessibility, or as an adjunctive procedure.  
3. Wide. A wide margin is accomplished by a procedure in which the lesion, its pseudocapsule 
and/or reactive zone, and a surrounding cuff of normal tissue are taken as a single block. The plane 
of dissection is entirely through normal tissue but within the involved compartment. No effort is 
made to remove the entire length of involved muscle from origin to insertion or bone from joint to 
joint. The local wide procedure probably corresponds to what is referred to as “wide local 
excision,” “en bloc excision,” and “radical en bloc excision.” A wide margin is definitive surgical 
management for Stage I lesions and can usually be accomplished by a local procedure for IA lesion 
Because Stage IB lesions usually involve some combination of bone, soft parts, and neurovascular 
structures, amputation is more likely to be required.  
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4. Radical. A radical margin is achieved by a procedure in which the lesion, pseudocapsule, 
reactive zone, and the entire muscles or bone involved are removed as one block. Longitudinally, 
the plane of dissection goes through or beyond the joint proximally and distally to the bone involved 
and through the tendinous origin and insertion of involved muscles. Transversely, the dissection 
passes beyond the major fascial septa of the involved soft tissue compartments or beyond the 
periosteum of intraosseous lesions. A radical margin does not necessarily imply a greater distance 
from the lesion to the margin of the wound than a wide margin. A margin on the other side of the 
intermuscular septum of a lesion in the vastus lateralis will constitute a radical margin but may be 
considerably closer than a wide margin achieved by amputation. A radical margin is definitive for 
Stage I1 lesions. A radical local resection can often be done for a Stage IIA lesion. If a lesion 
involves more than one compartment, or extends into or arises in the extracompartmental planes or 
spaces, compartmental containment is lost, and a radical margin is usually not attainable with a 
local procedure. Thus, radical amputation is usually carried out to achieve a radical margin in 
Stage IIB lesions, and it often requires a disarticulation or amputation proximal to the joint in 
question.” [81]  
 
The Enneking principles of margins are based on extremity sarcoma and reflects 
compartmental excision and amputation. In the abdomen, compartments are not 
clearly defined; however, covering intact peritoneum is considered to be a sufficient 
anatomical barrier [82].  
 The impact of margin status on GIST prognosis is under debate and some 
studies show no difference for patients operated with microscopically positive 
margins (R1 resection) compared to R0 resection. However, in paper II we show a 
favorable outcome when obtaining wide surgical margins [83]. In this context, a 
wide margin is defined as ≥2 cm margin and/or intact peritoneal coverage of the 
tumor (Figure 5). This may involve resection of organs adherent to or in close 







Figure 5. Schematic drawing of ideal resection of GIST with wide surgical margin ≥2 cm, located in stomach 




The surgical technique should command minimal contact with the tumor. Typically, 
a circular gastric resection or a small bowel resection with ≥2 cm margin is 
performed. Laparoscopic technique can be considered for selected cases, yet it is 
essential that damage to the tumor be avoided. Unlike epithelial-origin cancer, such 
as colorectal cancer, sarcoma originates from wall layers with significantly less 
protective membranes. Not infrequently is there only a thin layer of peritoneum or 
serosa surrounding the tumor tissue and damage to this barrier significantly 




Figure 6. Resection of small bowel GIST. Open laparotomy is the most common approach due to large tumor, 




2.6 FOLLOW-UP AND ADJUVANT THERAPY 
There is still a risk for recurrent disease even after complete resection of GIST, 
either locoregionally or metastatically, mainly to the liver. Prognostic assessment of 
risk for recurrence, metastasis and/or death is mandatory upon GIST resection. 
Several grading systems have been proposed and evaluated. With small differences, 
all commonly used evaluation methods predict tumors with high risk for recurrence 
yet there are differences in the intermediate risk-groups [84, 85]. Still, there is no 
consensus on which grading system provides the most accurate risk estimation [86]. 
There are currently three main categorical grading systems that divide risk 
categories in different tiers. The National Institutes of Health (NIH) system 
proposed by Fletcher et al. is based on tumor size and mitotic index [87]. This 
system later evolved into the AFIP (Armed Forces Institute of Pathology) criteria 
that, based on long term follow-up studies, also accounts for the observation that 
gastric GIST generally has a better prognosis and incorporates the primary tumor’s 
anatomic site as a risk factor[52, 88, 89]. At present, one of the most established 
grading systems, currently in wide use for clinical assessment of risk for recurrence, 
is the modified NIH criteria (Table 2), based upon tumor site, size, presence of 
mitoses and tumor rupture as an individual factor for high risk of recurrent disease 





(per 50 HPFs) 
Primary 
tumor site 
Very low <2.0 ≤5 Any 
Low 2.1-5.0 ≤5 Any 
Intermediate 2.1-5.0 >5 Gastric 
 <5.0 6-10 Any 
 5.1-10.0 ≤5 Gastric 
High Any Any Tumor rupture 
 >10 Any Any 
 Any >10 Any 
 >5.0 >5 Any 
 2.1-5.0 >5 Nongastric 
 5.1-10.0 ≤5 Nongastric 
 
Table 2. Modified NIH consensus criteria for risk of recurrence after R0 resected GIST. 
Adapted from Joensuu 2008[90]. HPF - high power field. 
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Some authors have also proposed the use of continuous risk stratification systems 
such as nomograms [91-93] or contour heat-maps that account for a non-linear 
relationship between tumor size and recurrence risk [85]. An example of a 
nomogram for estimation of recurrence-free survival after resection of GIST is the 
Memorial Sloan Kettering (MSKCC) nomogram, proposed by Gold et al. [91]. In 
this nomogram prognostic factors such as size, mitotic index and site are considered 
and each are assigned a point which is then summarized and read as probability for 




Figure 7. The MSKCC nomogram for estimation of recurrence risk after resection of GIST [91]. Reprinted 
with permission from the publisher.  
 
Cases with a high risk for recurrence should be offered adjuvant therapy with TKI 
after discussion with a multidisciplinary board. Notably, in patients treated with 
neoadjuvant imatinib, the mitotic count is not assessable for risk evaluation since the 
treatment effect down-regulates proliferation. This is often not a problem in clinical 
practice since the tumors eligible for neoadjuvant therapy have other features 
placing them in the high-risk group. The caveat are esophageal and rectal GISTs 
where the anatomical location often mandates neoadjuvant imatinib. In these cases, 
the MDT suggestion of adjuvant imatinib need to be based upon pragmatic 
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principles and if the treatment has not caused severe side effects, it is usually 
completed. If imatinib is discontinued, close follow-ups during the first years may 
be warranted. The duration of adjuvant therapy is still debated. Adjuvant treatment 
started following the ACOSOG Z9001 phase III double-blinded, randomized clinical 
trial showing improved progression-free survival (PFS) in patients receiving one-
year adjuvant imatinib as compared to placebo [94]. No difference in overall 
survival (OS) was observed in this study. The Scandinavian Sarcoma Group (SSG) 
conducted a study comparing 1 versus 3 years of imatinib (SSG study no. 18, 
abbreviated SSGXVIII), showing further improvements in PFS but also OS [95]. 
Based on these results the generally accepted treatment time is now three years. A 
recently published long-term follow-up study of the SSGXVIII cohort further 
emphasizes this strategy and shows a clear benefit in terms of OS in the group 
treated 3 years with adjuvant imatinib as compared to one year [96]. The ongoing 
SSGXXII trial evaluates potential benefits with prolonged adjuvant treatment of up 
to five years after surgery (ClinicalTrials.gov Identifier: NCT02413736). This study 
is a complement to a phase 2 safety study (PERCIST-5), which showed no 
recurrences during 5 years with imatinib treatment of resected GIST patients, 
however, the study had a high degree of early drop-out (49%) [97]. 
 There is no clear consensus on duration and intervals for follow-up after 
resection of GIST with or without adjuvant therapy. However, it is well known that 
even “low-risk” GISTs may recur and often later than high-risk tumors [52, 98]. 
This must be considered when planning follow-ups. Further, a higher risk of 
recurrences is observed after cessation of adjuvant treatment, why these patients 
may benefit from closer follow-ups after ending imatinib medication [71].  
 D’Ambrosio et al. have evaluated a protocol where 233 patients without TKI 
treatment were followed for a median of 68.3 months (95% CI=59.8–76.8). During 
follow-up, recurrent disease was detected in 40.3% of the patients and in 26.6% 
other cancers were detected. The protocol comprised clinical examinations and CTs 
every 3–4 months during the first 3 years, every 6 months year 4-5 and annually 
thereafter for up to ten years in intermediate/moderate- and high-risk patients. For 
patients with low- and very low-risk, clinical examinations and CTs were performed 
every 6 months for 5 years and thereafter annually up to ten years [99]. This 
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protocol is in accordance with the follow-up routines at our institution where we 
generally perform a CT or MRI of the abdomen every six months for five years and 
then annually for up to ten years. In selected cases with a high risk of recurrence 
according to risk stratification or uncertain margins, shorter intervals during the first 
years may be recommended after the MDT conference. 
2.7 IMATINIB RESISTANCE 
While most c-kit mutated GISTs are sensitive to imatinib treatment, there are certain 
mutations that are primarily resistant. In Exon 11 mutated GIST, 95% are primarily 
sensitive. Exon 9 mutated tumors are sensitive but higher doses of imatinib are 
proposed for patients with these mutations and those cases treated with standard 
doses may be perceived as primarily resistant [72]. The most common PDGFRA 
mutation in GIST is D842V on Exon 18 and is primarily completely resistant to 
imatinib [45, 62].  
 A common problem is the development of secondary resistance, which is 
typically seen after about two to two and a half years of imatinib treatment of 
primarily sensitive tumors. In many cases resistance is caused by secondary 
mutations that alter the configuration of the receptor, i.e. c-kit exon 13,14, 17 or 18 
[48]. These mutations are seen in about 67% of secondary resistant GIST [62]. It is 
not known if secondary mutations develop during the course of treatment or are 
present at start of treatment and clonally expanded under selection pressure from the 
treatment. Interestingly, secondary mutations do not seem to explain all cases of 
secondary resistance and there is data on the positive effect of dose escalation in 
cases of secondary progression during imatinib treatment [48]. There is also data, 
primarily from CML, on the effect of altered drug transporter expression. For 
example, cell-lines transfected with a mutated variant of the transport protein 
ABCB1 showed lower intracellular uptake of imatinib and lower antiproliferative 
effect [100]. Polymorphism in the drug transporter ABCG2/BCRP is also implicated 
in differences in the uptake of many drugs, including imatinib [101]. In Paper III, 
we explore this possible mechanism of resistance.  
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2.8 OTHER TKI’S 
After discovering imatinib, a plethora of tyrosine kinase inhibitors have been added 
to the family and still more are being developed. The U.S. Food and Drug 
Administration (FDA) approved Sunitinib in 2006 as second-line treatment of GIST 
when progression occurs during treatment with imatinib. Sunitinib blocks KIT, 
PDGFR, vascular endothelial growth factor receptor (VEGFR) and RET. It is 
administered orally in doses of 37.5 to 50 mg and a regimen of 4 weeks treatment 
followed by a two-week pause is recommended. As third-line treatment regorafenib 
was approved by the FDA in 2013 [102]. Many other TKIs have been and are still 
undergoing trials and the current situation for advanced GIST after imatinib failure 







TKI Affinity Clinical trial  Phase Line ORR  
mPFS 
(months) 
Sunitinib KIT, PDGFR, VEGFR, 
RET Demetri 2006 [103] III 2 7% 6.4 
Regorafenib 
KIT, PDGFR, RET, 
RAF1, BRAF, FGFR 
VEGFR1-3, TIE-2,  
Demetri 2013 [104] III 3  4.5% 4.8 
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Masitinib KIT (exon 9 & 11) 
highly selective 










Ponatinib BCR-ABL, KIT NCT03171389 II ≥2  recruiting 
Dovitinib VEGFR, FGFR, KIT, 
PDGFR-β 
Kang 2013 [115] 










CRAF, V600E BRAF, 
KIT, FLT-3 VEGFR, 
PDGFR-β 
Kindler 2011 [117] 









Crenolanib PDGFRA NCT02847429 III any  recruiting D842V 
 
 
Table 4. TKI with KIT inbititory activity in trials with advanced/metastatic GIST after imatinib failure. mPFS 
– median progression-free survival. * Subset analysis of D842V mutated patients (n=56). Adapted from 





2.9 TKI SIDE EFFECTS 
Target treatment with TKI is generally well tolerated as compared to conventional 
cytotoxic drugs. Still, more than 95% of TKI treated patients experience side-effects 
[120]. Most side effects are mild and tolerable but serious adverse effects need to be 
considered and monitoring of patients on TKI treatment is recommended. In some 
cases, adverse effects can be managed by dose reduction, whereas in other cases 
discontinuance of medication or changing to a different line of TKI is necessary 
[71].  
 Imatinib commonly causes nausea, fatigue, fluid retention/edema and in some 
cases skin rashes. These side effects are often manageable on the standard dose of 
400 mg daily [121]. Hematological side effects with myelosuppression causing mild 
anemia are common. In rare cases, severe anemia or agranulocytosis is observed. 
More infrequently, liver failure/hepatitis may occur [122]. There are a few case 
reports on fatal liver failure caused by imatinib [123-125]. Often early signs of liver 
failure are detected during monitoring and may be reversible through dose reduction, 
yet may infer cessation of imatinib therapy [126]. The relationship of liver failure 
during imatinib treatment and concomitant treatment with acetaminophen 
(paracetamol) has been investigated and in a mouse model co-administration of the 
two drugs induced irreversible liver damage [127]. In clinical practice, we advise 
patients on imatinib to avoid acetaminophen. Imatinib has, in most studies, not been 
shown to cause hypothyroidism but interacts with levothyroxine and in patients with 
hypothyroidism, an escalation of levothyroxine dose may be required to maintain 
euthyroid levels [128, 129].  
 Second-line TKI sunitinib has a similar side effect profile to imatinib and yet 
additionally, stomatitis, hand-foot syndrome, hypertension and hypothyroidism are 
more common in patients treated with sunitinib [120]. Third-line TKI regorafenib 
shares the same panorama of side effects as sunitinib [104]. Novel TKIs, such as 
avapritinib and ripritinib, have in studies, shown side effect profiles comparable to 
those of imatinib with nausea, vomiting and periorbital edema. Adverse effects were 
in most cases mild and tolerable, however,  9-11% of study patients dropped out 
from the study due to side effects [61].  
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3 SARCOMA OF THE BREAST 
Like sarcomas in other parts of the body, breast sarcomas consist of many different 
histopathological subtypes. Sarcoma accounts for about 1% of all breast 
malignancies, the most common histopathological subtypes being angiosarcoma and 
malignant phyllodes tumors but a large variety of more uncommon diagnoses are 
present. The annual incidence of breast sarcoma is reported to be 0.4/100 000 
persons [15, 130, 131]. Often breast sarcomas are detected as a palpable mass, 
though smaller in size than abdominal/retro-peritoneal sarcomas. Surgical resection 
can be curative, although recurrence rates are high even following surgery with clear 
margins [132, 133].  
3.1 ANGIOSARCOMA 
Angiosarcoma is derived from endothelial cells of blood or lymphatic vessels. Like 
most other sarcomas, it can develop in all parts of the body but the most common 
site is head/neck, including scalp. Angiosarcoma is one of the most common 
sarcomas of the breast and is usually divided into primary and secondary 
angiosarcomas where the primary presents in younger women without known 
exposure to risk factors [134]. Secondary angiosarcoma presents in older women, 
often 5-15 years after radiotherapy to the breast. Previous irradiation is a known risk 
factor for its development [135, 136]. Causal links to individual susceptibility 
dependent upon gene-environment interactions have been suggested [137]. Stewart 
Treves syndrome, the term coined after the authors of a report of six cases of 
angiosarcoma in 1948, i.e. chronic lymphoedema following a mastectomy with 
lymph node dissection in combination with irradiation, is another reported risk 
factor for lymphangiosarcoma [138, 139]. 
 Angiosarcomas are aggressive tumors with a high risk of local recurrences and 
dissemination, most commonly lung metastases. The 5-year over-all or disease 
specific survival is reported to be between 31-43% [133, 140, 141]. The median 
over-all survival for patients with local angiosarcoma in the breast has been reported 
to be 3.6 ± 1 year, but for patients who were diagnosed with metastatic disease 
median over-all survival was 0.7 ± 0.2 years [140]. 
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 Primary surgery with negative margins is recommended and in combination 
with tumor grade are shown to be the primary factors influencing prognosis [142]. In 
fact, some authors recommend excision of the entire radiated area in cases of 
radiation-associated angiosarcoma, due to the tumors’ propensity to multi-focal and 
diffuse growth [133, 143, 144].  
3.2 PHYLLODES TUMORS 
Phyllodes tumors are fibroepithelial tumors, first described by the German 
pathologist Johannes Müller 1831. The original term describing these tumors was 
cystosarcoma phyllodes, derived from the Greek word phullṓdēs, meaning, 
“resembling a leaf”, based upon their leaf-like features in the microscope. However, 
these tumors are rarely cystic [145].  
 The annual incidence is reported to be 2.1 per million, and the tumor can affect 
patients of all ages with a peak at 41-50 years (range 8-89) [146, 147]. Phyllodes 
tumors are composed of both epithelial cells and connective tissue stroma and range 
from benign (grade 1) over to borderline (grade 2) and to overtly malignant (grade 
3). Grading is based upon several histopathological features, including stromal 
cellularity, overgrowth and atypia, mitoses and tumor border (well defined or 
permeative). The three tier classification was first introduced by Azzopardi in 1979, 
subsequently refined by Salvadori in 1989 [147] and has later been included in the 
WHO classification of bone and soft tissue tumors [148]. The malignant phyllodes 
tumors have a higher proportion of mesenchymal proliferation and a genetic profile 
similar to other breast sarcomas, though not to angiosarcoma [149]. 
 Owing to the spectrum of behavior in the different grades of differentiation of 
phyllodes tumors, surgical treatment should be individualized. In a review, Tan et al. 
summarized the literature on surgical margins and concluded that firm evidence on 
appropriate margins in Phyllodes tumors are lacking. Based upon available data, the 
recommendation in this study was to excise recurrent or malignant phyllodes tumors 
with negative margins of >1 mm, whereas benign phyllodes tumors may be treated 
expectantly. Lymph node dissection is not recommended [150]. Zhou et al. also 
reviewed the literature and found that surgical margins were reported to have an 
impact on recurrence rates in 15 of 24 reviewed articles, yet did not define any 
recommendations on the extent of margin [151]. In a Canadian study, margin status 
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has been addressed. No significant difference in local recurrence rates was observed 
when margins of >2 mm, 2-10 mm and >10 mm were compared but positive 
margins implied an elevated risk for local recurrence. Of 49 patients with malignant 
phyllodes, 24 were treated with mastectomy and none of these had local recurrence. 
In the 25 patients treated with breast conserving surgery, 7 local recurrences (28%) 
were observed during a median follow-up of 65 months (range 0.5-197) [152]. 
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4 AIMS OF THE THESIS 
This thesis aims to increase the knowledge of sarcoma management and especially 
GIST, the most common intraabdominal sarcoma. The project envisioned a 




• To explore a possible mechanism for imatinib resistance in GIST 
• To asses the importance of surgical technique in treatment of GIST 
• To explore possible underlying factors for the increasing incidence of 






5 PATIENTS AND METHODS 
5.1 PAPER I 
Cell cultures with known imatinib-sensitivity (GIST882) and resistance (GIST48) 
were cultivated for 4-5 days until near-total confluence. The cultures were then 
exposed to imatinib in concentrations of 1100 to 3300 ng/ml for three hours at 37°C 
in 5% CO2 atmosphere. After washing, cells were detached with trypsin and spun 
down. The pellet was snap-frozen to -80°C pending analysis. We also collected 
tissue (tumor and adipose) and blood plasma from three patients undergoing surgery 
with ongoing imatinib treatment. All patients in this study were taking 400 mg 
imatinib orally per day. Imatinib concentrations were measured using liquid 
chromatography with coupled mass-spectrometry and time of flight detection. This 
method was first described by Elhamili and Bergquist [153] and this paper is a 
proof-of-concept study on applying the method for intra-cellular concentration 
measurements in GIST-cells from cell culture and tumor tissue. 
5.2 PAPER II 
One hundred twenty-nine patients undergoing surgery for GIST at Karolinska 
University hospital, in whom surgical margins were assessed at the time of 
resection, were included. Patients were classified as non-metastatic at diagnosis and 
without TKI treatment (nonMET/nonTKI n=79), as patients with metastatic disease 
at diagnosis (n=14) and patients without metastases at diagnosis, yet with TKI 
treatment pre- or post-surgery (nonMET n=36), (Figure 8).  
 Patient data including age, gender, tumor size, site, risk group, according to 
modified NIH criteria [90], and treatment were recorded. Patients were followed 
regarding recurrence, distant metastasis and survival. Median follow-up time was 76 
months (range 10–179). 
 Tumor size was recorded based on histopathological reports. Tumors were 
grouped based on greatest diameter and anatomic location. All 115 patients who 
were without metastasis at diagnosis, regardless of TKI treatment (GIST-nonMet) 
were analyzed, but in order to avoid confounding as to the effects of TKI, the 
subgroup of 79 patients with non-metastatic disease and no TKI treatment was 




The Kaplan–Meier method and log-rank test were used to compare time from 
diagnosis to local/peritoneal recurrence or metastasis, time to death from any cause 
and time to death from disease. Multivariate analysis with Cox proportional hazards 
model was used to compare prognostic factors. All tests were performed two-tailed 
and p values <0.05 were considered to be statistically significant.  
 
 
5.3 PAPER III 
A series of consecutive patients with GISTs pre-treated with imatinib and 
undergoing tumor resection at our department from 2013 to 2017 were included 
after informed consent. The included patients had either metastatic disease or locally 
advanced and primarily non-resectable tumors. At the time of surgery, samples from 
tumor, normal tissue and blood plasma were collected. After resection, the tumor 
was incised and samples were collected from peripheral and central parts. In some 
cases, with larger tumors, additional samples were collected from the intermediate 
part of the tumor (Figure 9). In cases with multiple tumor locations samples could be 
obtained from different tumors.  
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 All samples were instantly frozen on dry ice and transported to -80°C freezer. 
Clinical data was retrieved from patient medical records. In relevant cases, the 
radiological response was evaluated during the pre-treatment period and CT scans 
performed prior to treatment were compared to the latest pre-operative CTs 
according to Choi criteria. The histopathological response was assessed and graded 
based on the proportion of viable tumor cells. Mutation analyses were performed in 
order to determine mutational status of KIT and PDGFRA genes, using bidirectional 
sequencing with Genetic Analyzer 3500 or Genetic Analyzer 3130xl (Applied 
Biosystems, Foster city USA). Analytic software Mutation Surveyor SoftGenetics 
LLC v4.0.4 was used. The imatinib concentration in plasma and tissue samples was 
analyzed using ultra-performed supercritical fluid chromatography-tandem mass 
spectrometry. The analysis protocol was an improved and validated version of that 
described in Paper I, where the internal standard for these analyses was deuterium-
marked imatinib (imatinib D8). All analyses were run in duplicates.  
 Tissue was collected in connection with surgery and was analyzed on 
Formalin-fixed paraffin-embedded (FFPE) samples. Using conventional 
immunohistochemistry, these were stained with antibodies for drug transporters 
(rabbit monoclonal anti-MDR1/ABCB1 (clone E1Y7S) at 1:400, rabbit monoclonal 
anti-ABCG2 (clone D5V2K) at 1:350; both from Cell Signaling Technology, 
Danvers, MA, USA and mouse monoclonal anti-OCT1/Pou2f1 (clone 12F11) at 
1:100 from Santa Cruz Biotechnology, Dallas, TX, USA). An experienced 
central peripheral 
intermediate 
Figure 9. Acquisition of samples from different parts of resected tumors. 
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pathologist reviewed the slides and the expression was graded as low, intermediate 
or high. The same pathologist, who was blinded from concentration analysis results, 




Since data was not normally distributed, non-parametrical tests, Mann-Whitney, 
Wilcoxon signed ranks and Kruskal-Wallis, were used to calculate correlations. For 
correlations between histological features, Fisher´s exact test was used. A level of 
p<0.05 was considered statistically significant. 
5.4 PAPER IV 
In this case-control study, Swedish national registries were used to identify 344 
patients with mesenchymal tumors in the breast diagnosed between 1993-2013. 
These were classified according to reported histopathology and each case was 
matched according to age and sex to up to ten controls. Incidence was analyzed and 
compared for 5-year periods during the study time. The cases were compared to 
controls regarding previous cancer history, where breast cancer and other cancers 
were analyzed separately. We also analyzed socioeconomic factors and survival. 
 
Statistical analysis 
Incidence was calculated using Poisson regression. Kaplan-Meier and Cox 
regression analyses were used for survival analyses and conditional logistic 






6.1 PAPER I 
Significantly differing concentrations were observed in cell cultures exposed to 
imatinib at high or low concentration. There was also a significant difference in 
concentrations between the two cell lines used, where the imatinib-sensitive cell line 
GIST882 had higher intracellular imatinib concentrations than the imatinib-resistant 
GIST48. Repeated experiments showed high reproducibility of the measurements. 
Negative controls were performed and, as expected, showed no intracellular 
imatinib. In patient samples, large inter- and intra-tumor variability regarding 
imatinib concentrations were observed. Generally, a higher imatinib concentration 
was observed in tumor tissue than in normal adipose tissue.  
6.2 PAPER II 
In the group of 79 patients without TKI treatment, 31 (39%) developed 
local/peritoneal recurrence and/or metastases. Thirteen patients (16%) died from 
disease during follow-up, of which 5 died from local/peritoneal disease without 
distant metastasis. The 5-year OS was 86%. Thirty-nine patients had surgery with a 
wide margin, 2 of these died during follow-up, but none from GIST. Of 22 patients 
operated with marginal margin, 5 died, of whom two from the disease. In 18 patients 
who had intralesional surgery, 4 patients died within 5 years, all from 
recurrent/metastatic GIST.  
 The risk for local/peritoneal recurrence was higher for patients with marginal 
margin HR 6.8 (1.4–32.7) and intralesional margin HR 13.5 (3–61) as compared to 
wide margin (p=0.003). The surgical margin remained an independent risk factor for 
local recurrence in multivariate analysis after adjusting for tumor size, mitotic index 
and site. The results were similar when the entire group of 115 patients with non-





6.3 PAPER III 
Twenty-one patients with imatinib-treated advanced and/or metastatic GISTs were 
included. The imatinib concentration in tumor tissue, normal tissue and plasma 
showed great variability and no significant correlation between these was found. 
Also, imatinib concentrations did not correlate to BMI, duration of treatment or c-
kit/PDGFRA mutational status. The histopathological response was correlated with 
absent expression of efflux drug transporters ABCG2 and MDR1 and not to imatinib 
concentrations in plasma or tumor tissue. Absent immunostaining for ABCG2 was 
significantly associated with a lower mitotic activity (Fisher´s exact test p <0.001). 
Positive staining for MDR1 (p<0.001, Fisher’s exact test) or ABCG2 (p=0.11, 
Fisher’s exact test) was associated with a higher proportion of viable tumor.  
6.4 PAPER IV 
Annual breast sarcoma incidence increased from a mean of 1.52 cases per million, 
during the first half of the study period to 2.04 during the second half and the 
incidence of angiosarcoma increased 4-fold from 0.09 per million per year during 
the first period, 1993-1998, to 0.42 in 2009-2013 (trend of increase in the incidence: 
1.10, 95% CI 1.05-1.16; p<0.001). Angiosarcoma patients were heavily 
overrepresented, having a history of breast cancer compared with controls. The 
highest risk association was observed 5-10 years after breast cancer diagnosis (OR 
167, CI 95% 35.1-791; p<0.001). Survival analyses showed a median survival time 
for angiosarcoma patients of 4.4 years (95% CI 3.13-6.17) and unspecified sarcoma 
5.7 years (95% CI 0-11.6). Interestingly, borderline phyllodes tumors had no 
significant differences in survival when compared to benign phyllodes or controls, 
whereas survival for patients with malignant phyllodes tumors was more similar to 





This thesis work spans from the basic lab-bench methods to epidemiological registry 
studies. The translational approach is appropriate for studies on sarcoma and indeed, 
applicable in daily clinical work. Understanding of different tumor´s growth pattern, 
prevalence in the population, molecular aberrations and potential treatment targets, 
helps clinical decision-making. Collaboration in multidisciplinary teams not only 
facilitates this, but has also been shown to improve patient outcomes [31]. Since the 
knowledge about sarcomas is rapidly evolving, clinicians must have insight into 
current research methods and results. 
 
In paper I, we used an established analytical method, LC/MS-TOF, and validated a 
new protocol for measuring plasma- and intracellular imatinib concentrations in the 
nanomolar range. The results were robust and reproducible and the protocol has later 
been used in other studies[154, 155]. In our series, intracellular imatinib 
concentrations in cultured cells were dependent upon exposure to different doses of 
the drug, yet also on the imatinib resistance of the cell-line, where imatinib-resistant 
cells had a lower intracellular concentration when exposed to an equal dose. Based 
on these findings, a mechanism of imatinib uptake into the cell or efflux from the 
cell was suspected and studied further in paper III. In patient samples, we noticed 
large variability in intra- and intertumoral imatinib concentrations. Imatinib 
concentrations were higher in tumor tissue than in plasma. 
 
Key findings: 
• Intracellular concentration of imatinib in GIST cells is measurable and 
measurements are robust and reproducible 
• Imatinib-resistant cells (GIST48) had significantly lower imatinib 






In paper II we demonstrate the importance of wide surgical margin and careful 
technique when resecting a GIST. The reason for conducting this study was a 
clinical observation of higher rates of recurrences in GIST patients operated with 
small or no margins. It is also well established that pre- or intraoperative tumor 
rupture is a risk factor and this has been included in the modified NIH risk 
assessment system. The strength of this study was that the surgeon assessed margins 
at the time of resection. When the pathologist assesses margins the specimens may 
have been damaged in transport and the thin peritoneal coverage may be fractured, 
resulting in the microscopic finding of tumor-growth in the resection border, i.e. R1. 
Another effect on the specimen after resection is the contraction of especially the 
gastric wall, which may cause separation of the mucosa and the muscle-layers, thus 
exposing the tumor. Thirdly, not all GISTs are rapidly growing and in case of an R1 
resection it may take many years for the microscopic residual tissue to grow back 
into a clinically detectable tumor. Although rare, recurrent GIST has been reported 
up to 20 years after resection of the primary tumor [98].  
 The findings in this study are not uncontroversial and there are several 
contradictory reports in which R1 resected patients show a prognosis comparable to 
those with negative resection margins. A recent report from Oslo showed that tumor 
rupture is an adverse prognostic factor, though minor damage to the peritoneal 
coverage or R1 resection did not carry a significantly worse prognosis. The authors 
conclude that the recurrence risk associated to R1 resection is in fact confounded by 
tumor rupture. Four hundred and ten patients were followed for a median of 45 
months (range 0-175). Fifty-two patients had tumor rupture and 39 of these had 
recurrent disease. Forty-seven patients had R1 resection, of whom 17 developed 
recurrent disease. No recurrences were recorded in 24 patients with non-high-risk 
tumors who received an R1 resection, while recurrence was recorded in two out of 
seven patients with high-risk tumors [156]. It is not surprising to see the high 
recurrence risk after tumor rupture. The relatively low number of recurrences in R1 
resected patients might be explained by a relatively short follow-up time, or possibly 
the use of adjuvant imatinib treatment. 
 In contrast, a study by Rutkowski et al. identified risk factors for recurrence in 
335 GIST patients with a median follow-up of 31 months (range 4–292 months). 
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The significant predictors for recurrence were size, site, high mitotic count, male 
gender and R1 resection. Notably, only 6% had a known GIST diagnosis prior to 
surgery [157]. Ahmed et al. reported their experience of GIST in the mid-Trent 
region, UK. In total, 185 patients where studied of whom 155 had surgical resection 
of GIST. Of these, 79 had documented R0, 11 had R1 and 15 had R2 resections. For 
the remaining 48 patients, no data on the resection margin was available. No 
statistical analysis is presented in this study on margins versus recurrence, but in the 
R1 resected patients 4 had intermediate risk according to NIH criteria and 50% (2/4) 
developed recurrence. Five patients had high risk and of these 100% (5/5) had 
recurrent disease. No recurrences were recorded in the low-risk group. Median 
follow up was 4.2 years (range 0.5-15). This study is difficult to interpret since 
conclusive data on risk factors for recurrent disease is lacking. Also, data on surgical 
margin is missing in more than 25% of the study population. However, the authors 
conclude that R1 resection is a risk factor for recurrence in intermediate and high-
risk tumors [158].  
 A meta-analysis of twelve studies including 1 905 patients with resected GIST 
show negative impact on disease-free survival in patients who had R1 resection 
compared to R0 (HR 1.596, 95% CI 1.128–2.258), but not on overall survival (HR 
1.430, 95% CI 0.608–3.363). The negative effect of microscopically positive 
margins was mitigated by imatinib treatment [159].  
 Although our study (Paper II) showed beneficial effects of R0 compared with 
R1 resection, the primary end point was to investigate the effects of wide margins. 
Both marginal and wide margins are R0. When excluding the patients operated with 
wide margins and analyzing intralesional (R1) versus marginal (R0) margins, the 
differences between the groups were no longer significant, which may help in 
understanding the findings in some of the previous studies that fail to show a 
positive effect of R0 versus R1 surgery in GIST, since the difference is, at least in 
our material, explained by the wide margins. Adjusting for tumor size, site and 
mitotic index, wide surgical margin was still an independent positive prognostic 
factor for recurrence-free survival. According to our definition of margin, all 
ruptured tumors are considered to have intralesional margins, regardless of the time 




• Excision of GIST with a wide surgical margin improves progression-free 
and disease-specific survival 
• Margin status is an independent risk factor regardless of tumor size mitotic 
index, and site 
• When excluding patients operated with a wide margin, the prognostic 
impact of R0 versus R1 resection was no longer significant  
 
 
In paper III, we used an improved protocol of the analytical methods described in 
paper I to measure drug concentration in GIST cells from patients treated with 
imatinib prior to surgery. In this expanded cohort of patients, we could confirm the 
previous findings of great variability in imatinib concentrations, not only between 
different subjects, but also between different parts of the same tumor. The plasma 
levels were generally in line with expected results. Previous data has shown 
beneficial effect of imatinib plasma concentrations above 1100 ng/ml (2.23 µM) 
[160]. In the current study, mean plasma concentration was 2.16 µM (range 0.60-
3.68 µM). However, concentrations above or below the cut-off proposed by Demetri 
et al. could not be correlated to either radiological or histological response. In fact, 
no correlations were found between plasma or tissue concentrations and response. 
This finding was somewhat surprising. Since all analyses were performed at the 
same time and using the same protocol for preparation and run in duplicates with 
small differences, the risk for methodological error as an explanation for this finding 
is low. However, considering the limited and relatively heterogeneous patient 
cohort, a type II error cannot be ruled out. On the other hand, the measurements of 
intracellular, or tumor tissue, imatinib is considered to reflect the total imatinib 
content, not accounting for sequestration in subcellular compartments or protein 
binding. Imatinib is bound to a1-acid glycoprotein to a large extent (>96%) [161]. 
This may imply that the total imatinib concentration is not predictive for response, 
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since only a minor and individually variable portion is free and available to reach its 
target site.  
 The hypothesis for this study was that acquired imatinib resistance could in 
part be explained by pharmacodynamic changes during tumor development, leading 
to decreased imatinib levels intracellularly. The finding that efflux protein 
expression was inversely correlated to response indicates that there might be some 
substance to this hypothesis, albeit not explained by changes in whole-cell imatinib 
concentration measurements. Interestingly, a recently published study on CML cell 
lines, that were rendered imatinib resistant by prolonged imatinib exposure, shows 
increased nilotinib effect when simultaneously blocking efflux transporter 
BRCP/ABCG2 [162]. To further explore TKI resistance mechanisms, studies of 
imatinib bioavailability and localization in subcellular compartments could be of 
interest but first, one would want to confirm the findings of MDR1 and ABCG2 
efflux transporters as prognostic markers in GIST. This could preferably be 
performed in a larger patient cohort and possibly with quantitative PCR. 
 
Key findings: 
• Efflux drug transporters ABCG2 and MDR1 expression is correlated to 
histologic response in GIST where absent expression is associated with 
better response 
• Intracellular imatinib concentration in GIST shows large variability and is 
not correlated to plasma levels or histopathological response 
 
 
The epidemiological project, paper IV, was initially intended to assess GIST 
incidence in Sweden and the potential risk factors for developing GIST. However, it 
became evident that GIST diagnosis was extremely difficult to identify accurately in 
the registers used and the aim of the study was shifted to sarcoma in general. As it 
turned out, the major finding of this registry study was the increasing incidence of 
angiosarcoma of the breast and a correlation to a previous history of breast 
carcinoma. This finding is also in line with clinical observations of an increasing 
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number of patients presenting with angiosarcoma approximately five to ten years 
after breast cancer diagnosis and treatment. This observation led us to undertake the 
current study. The association to breast cancer may not be an entirely novel finding 
and concern has been raised in previous studies that increased use of radiotherapy 
following breast conserving surgery may lead to more patients developing secondary 
angiosarcoma [163-166], however, our results confirm other studies. The strength of 
our study is the population-based approach and the adequacy of Swedish registries. 
A weakness is that radiation data was only available for a subset of the included 
patients. When considering the implications of our findings, the well documented 
positive effect of breast conserving surgery and subsequent radiotherapy must be 
taken into account. For example, a meta-analysis of 17 studies on BCS ± RT, 
comprising 10 801 women, showed a reduced risk of recurrence (ARR 15.7%, 95% 
CI 13.7–17.7, p<0.00001) and an all-cause mortality (ARR 300.6–5.4, p=0.03). In 
this material there are however, subgroups with a higher risk of recurrence and 
therefore differences in benefit from RT are identified. The high-risk features 
include lymph node metastasis, lumpectomy (compared to more extensive surgery), 
young age at diagnosis and high-grade tumors as well as older women with ER 
positive tumors not treated with anti-estrogens. The authors assigned the study 
population retrospectively into three risk groups based on these factors and found an 
ARR for recurrence in the high-risk group (1 924 patients) of 24.3% (95% CI 19.6-
29.0), in the intermediate group (3 763 patients) ARR was 12.4% (95% CI 9.7-15.1), 
whereas in the low risk group (1 600 patients) ARR was 6.9% (95% CI 2.2-11.6) 
[167].  
 Interestingly, a Swedish RCT by Wickberg et al. showed a protective effect by 
radiotherapy after breast-conserving surgery during the first five years after 
resection of the primary breast cancer, but no significant differences in survival at 20 
year follow-ups [168]. With the growing evidence for an increasing incidence of 
radiation-associated angiosarcoma there might be a reason for prospective risk 
assessment when recommending breast cancer treatment. For patients with high-risk 
features, radiotherapy is beneficial following breast cancer, however in the low-risk 
groups, the possible side effects may outweigh the small risk reduction added by 
RT. Moreover, radiotherapy is currently recommended for the treatment of ductal 
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breast cancer in situ (DCIS). While this entity is not invasive cancer, DCIS may 
progress in 36% of patients and is treated with a combination of surgery, hormone 
therapy and RT. No survival benefits have been demonstrated with these treatments 
and currently, trials are underway to evaluate watchful waiting [169]. 
 
Key findings: 
• The incidence of angiosarcoma of the breast increased 4-fold during a 21-
year period 
• Compared with the control population, patients with angiosarcoma were 
heavily over-represented with a history of breast cancer 
• Benign and borderline phyllodes tumors did not have a negative effect on 
survival but malignant phyllodes tumors had a poor prognosis, similar to 








• Imatinib is measurable intracellularly (proof-of-concept, paper I) and is 
accumulated in tissue, leading to higher tumor tissue levels than those in 
plasma. The tissue concentrations show large variability between and within 
different individuals and are not correlated to plasma concentration or 
response (paper III). 
 
• Expresion of cell membrane efflux transporters ABCG2 and MDR1 is 
associated with inferior response in imatinib treated GIST (paper III). 
 
• Adequate surgical technique with wide surgical margins and careful handling 
of the tumor in order to prevent tumor rupture is of prognostic importance in 
GIST (paper II). 
 
• The incidence of angiosarcoma of the breast is increasing in Sweden and 






9 SUMMARY IN SWEDISH 
Sarkom är samlingsnamnet för en grupp olikartade och ovanliga tumörer som utgår 
från så kallade mesenkymala celler. Denna celltyp finns i hela kroppen och är 
ursprung för t ex bindväv, blodkärl, fett, muskler och skelett. De flesta sarkom är 
elakartade och de kan uppstå var som helst i kroppen. Sarkom beräknas utgöra cirka 
1–2% av all cancer, och i dagsläget finns ett 100-tal olika varianter beskrivna. Det 
vanligaste sarkomet i bukhålan är gastrointestinal stromacellstumör (GIST), som 
årligen drabbar cirka 15 personer/miljon invånare. GIST uppkommer oftast i 
magsäcken (cirka 60%), följt av tunntarm (cirka 25–30%), men kan förekomma i 
hela magtarmkanalen. GIST i matstrupe, tolvfingertarm och ändtarm utgör cirka 3–
5% respektive och tumören är mycket ovanlig i tjocktarmen. GIST kan uppstå i alla 
åldrar, men är vanligast hos personer över 60 år och drabbar män och kvinnor i 
samma utsträckning. Symtom på GIST inkluderar blödning, tidig mättnadskänsla 
eller en kännbar knöl. Ungefär hälften av patienterna har inga symtom och tumören 
upptäcks då av en slump i samband med utredning eller operation av annan orsak. 
Behandlingen av GIST är i första hand kirurgi, men i de fall där tumören är 
avancerad eller om det finns tecken till spridning (metastaser) ges medicinsk 
onkologisk behandling, antingen som enda behandling, eller i syfte att krympa 
tumören och möjliggöra kirurgi. Onkologisk behandling kan också bli aktuell för att 
minska återfallsrisk efter operation, i synnerhet om ursprungstumören är stor, har 
hög celldelningstakt eller tecken på skadad tumörkapsel, s k perforation.  
 
Den cellulära mekanism som driver GIST är i de flesta fall en mutation i en 
tillväxtreceptor på cellytan; vanligast är KIT (75%) och PDGFRA (10%). Båda är så 
kallade tyrosinkinasreceptorer, och punktmutationer i genen som kodar för receptorn 
gör att “signal” ständigt är påslagen och stimulerar bl a celltillväxt och 
cellöverlevnad. Onkologisk behandling av GIST revolutionerades kring 
millennieskiftet då imatinib, en nyligen framtagen behandling mot kronisk lymfatisk 
leukemi, även visade sig vara mycket effektiv mot GIST. Vad imatinib gör är att 
selektivt blockera dessa receptorer, och slår på så vis av tillväxtsignalen. Införandet 
av imatinib förändrade dramatiskt utsikterna för patienter med GIST, och i många 
avseenden har GIST och imatinib blivit ett modellsystem för modern onkologisk 
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behandling. Gruppen av läkemedel, så kallade tyrosinkinashämmare, ofta förkortat 
TKI, har sedan vuxit stadigt och innefattar idag ett 10-tal registrerade varianter, och 
fler är på väg. Ett återkommande problem med TKI-behandling är att tumörcellerna 
efter hand ofta utvecklar motståndskraft, s k resistens, mot behandlingen vilket leder 
till återväxt av tumören.  
 
I delarbete I beskrivs en ny metod för att mäta koncentration av läkemedlet imatinib 
i GIST-celler, både från cellodling och från tumörer som avlägsnats kirurgiskt. I 
odlade celler uppmättes högre koncentrationer i en imatinibkänslig cellinje, jämfört 
med en imatinibresistent cellinje. I prover från patienter uppmättes ansamling av 
imatinib i tumörceller jämfört med nivåerna i plasma. Koncentrationerna i 
tumörceller och plasma skiljde sig mycket mellan olika individer. 
 
I delarbete II undersöktes betydelsen av kirurgisk marginal av frisk vävnad kring 
tumören vid resektion av GIST. De patienter som opererats med en så kallad ”vid 
marginal” med ≥2 cm frisk vävnad kring tumören uppvisade lägre risk för återfall 
jämfört med de patienter som opererats med mindre marginal (Hazard ratio 6.8 (1.4–
32.7) för marginell marginal respektive 13.5 (3–61) för intralesionell marginal (p = 
0.003)). 
 
Delarbete III är en fortsättningsstudie av delarbete I, och här studerades en större 
grupp av GIST-patienter vilka förbehandlats med imatinib inför kirurgi. Med en 
vidareutveckling av metoden från delarbete I mättes imatinibkoncentrationer i 
tumörceller och plasma. Dessutom studerades uttrycket av läkemedelstransport-
proteiner på tumörcellerna, eftersom imatinib aktivt behöver transporteras över 
cellmembranet för att utöva sin effekt. Resultaten visade stor variation avseende 
imatinibkoncentrationer och ingen signifikant koppling mellan nivåer i plasma och 
tumörceller, eller till effekt av behandlingen. Uttrycket av transportproteiner var 
däremot kopplat till behandlingseffekt, och ett lägre uttryck av utflödesproteinet 
ABCG2 var associerat till bättre effekt i form av låg celldelningstakt i tumören. 
Tumörceller som uttryckte antingen ABCG2 eller MDR1, båda utflödesproteiner, 
hade högre andel opåverkade (viabla) celler. 
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Sarkom kan, som nämnts ovan, uppstå i hela kroppen och i delarbete IV studerades 
förekomst av och prognos vid bröstsarkom. Patienter med sarkom i bröstet under 
perioden 1993–2013 jämfördes med en matchad kontrollgrupp som inte hade 
sarkom. Insjuknande i den ovanliga sjukdomen angiosarkom ökade fyrfaldigt under 
studieperioden. Angiosarkom är en ofta snabbt och diffust tillväxande tumör som 
utgår ifrån blod- eller lymfkärl, och spridning (metastasering) till lungorna är vanlig. 
Den förväntade överlevnaden är kort och aggressiv kirurgisk behandling kan krävas 
för att avlägsna tumören. Det har tidigare beskrivits att stålning är en riskfaktor för 
att utveckla angiosarkom. Flertalet av patienterna med angiosarkom i den aktuella 
studien hade tidigare behandlats för bröstcancer, en behandling som ofta innefattar 
strålning. Det fanns en tydlig skillnad mot kontrollgruppen avseende genomgången 
bröstcancer. Patienter med andra sarkomtyper i bröstet hade inte i lika hög grad en 
historia av bröstcancer.  
 
Sammanfattningsvis studeras i denna avhandling några av de ovanliga sjukdomar 
som ingår i gruppen sarkom. Resultaten visar en möjlig delförklaring till 
resistensmekanism mot läkemedelsbehandling av GIST. Fortsatta studier av detta är 
av värde, och det finns data från andra forskargrupper där farmakologisk påverkan 
av transportproteiner kan ha betydelse för effekt av TKI behandling. Vidare belyses 
vikten av korrekt kirurgisk teknik vid resektion av GIST, vilket är högaktuellt i 
diskussioner om nationell nivåstrukturering som pågår i Sverige. Slutligen visas att 
insjuknande i den ovanliga tumörsjukdomen angiosarkom i bröst ökar, och 
överrepresentation av tidigare bröstcancer tyder på en koppling till tidigare 
strålbehandling. Fortsatt vaksamhet på denna utveckling är motiverad. Samtliga 
studier har gjorts med utgångspunkt från kliniskt mycket relevanta problem, och 
resultaten har bitvis redan satt avtryck i den kliniska vardagen vid utredning, 
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